Accessibility Information

Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.

POTASSIUM IODIDE TABLETS, USP,

Solicitation Number: spm2dp11r0005
Agency: Defense Logistics Agency
Office: DLA Acquisition Locations
Location: DLA Troop Support - Medical
  • Print

Note:

There have been modifications to this notice. To view the most recent modification/amendment, click here
:
spm2dp11r0005
:
Solicitation
:
FAR 6.302-1(c) - Brand name
:
Added: Dec 12, 2011 10:21 am
POTASSIUM IODIDE TABLETS, USP, 130 MG POTASSIUM
IODIDE, INDIVIDUALLY SEALED IN FOIL WRAP, 14S
"IOSAT" NDC51803-0001-01
AAc "L"; u/i "pg" (14's indiv. sealed)
Added: Apr 09, 2012 2:14 pm
 

Justification for Other than Full and Open Competition Under Authority of


10 U.S.C. 2304(c)(1)


Potassium Iodide Tablets


 


•1.    The Defense Logistics Agency (DLA), Troop Support, Medical Supply Chain is the contracting activity. 


 


•2.    The action being approved is the ability to solicit for DLA requirements on an Other than Full and Open Competition basis.


 


•3.    Following are the supplies required to meet DLA's needs:


     Item Description: Potassium Iodide Tablets, USP,130 MG, Potassium Iodide, Individually Sealed in Foil Wrap, 14s


     NSN:  6505-01-496-4916


     Quantity:  75,000 PG


     Unit Price:  $5.23 (Based on the award made on 6/17/11 for 175 PG.)


     Number of Options:  None


                 Maximum Dollar Value:  $392,250.00


           


•4.    The applicable statutory authority permitting Other than Full and Open Competition is 10 U.S.C. 2304(c)(1), FAR Part 6.302-1(c), Only one responsible source and no other supplies or services will satisfy agency requirements.


 


•5.     The use of this authority is necessary because the USAMMA has submitted a MILSTRP for this item to ensure that critical operational forces are protected in the event of nuclear fallout.  The recent earthquake in Japan in March of 2011 and the resultant nuclear crisis has renewed interest in this item..


           


Anbex Inc. is the only FDA-approved manufacturer of the subject item. There are fourteen tablets in each package which will protect one adult for two weeks 


 


.The procurement history of the item indicated that awards were only made to Anbex Inc. and distributors offering the Anbex Inc. item.  If an offer is received from a new manufacturer of this item, FDA approval will be required prior to award.


 


The FDA recommends potassium iodide (KI) for thyroid blocking in radiation emergencies.  It can be used to provide safe and effective protection against thyroid cancer caused by irradiation.


 


•6.    This requirement was synopsized on 12/12/11 and on 1/26/12 in FedBizOpps.  In addition, this justification will be published with the solicitation in accordance with FAR 6.305(c).



 


•7.    As the Contracting Officer, I hereby determine that the anticipated cost to the Government will be fair and reasonable based on a comparison with Anbex Inc.'s lowest price catalog where the items are sold in substantial quantities to the general public.  Negotiations will be conducted to assure that the Government receives equal to or lower than the lowest price sale to the general public under terms and conditions that are comparable to those solicited by the Government.  It is anticipated that the price under this contract will represent the best value and lowest cost alternative (considering price and other factors).


 


•8.    DLA Troop Support performed market research through the internet, and DLA Troop Support Medical Supplier Operations Directorate, Pharmaceutical Manufacturer/Distributor Division, Technical/Quality Support Section.  This search revealed that Potassium Iodide Tablets, USP, 130 MG of Potassium Iodide, Individually Sealed in Foil Wrap, 14s, is only available from Anbex Inc. or distributors offering the item manufactured by Anbex Inc.


 


•9.    There are no other facts supporting the use of Other than Full and Open Competition.


 


•10.  Anbex Inc. has expressed an interest in this acquisition.


 


•11.  This agency will continue to survey the market in an attempt to remove or overcome any barriers to competition and identify additional sources before any subsequent acquisitions are initiated.


 


•12.  As the Contracting Officer, I hereby certify that this justification is accurate and complete to the best of my knowledge and belief.


 


 


 


___________                          ____________________________                                                                                                        
      Date  
                                                              
TINA BALLEZZI
  
                                                             Contracting Officer


 


 


 


Added: Aug 23, 2012 2:14 pm

 Solicitation SPM2DP11R0005 is cancelled in its entirety.

Please consult the list of document viewers if you cannot open a file.

Solicitation 1

Type:
Solicitation
Posted Date:
April 9, 2012
j&a combine 4916.pdf (5,225.92 Kb)
Description: Justification
:
700 Robbins Avenue
Philadelphia, Pennsylvania 19111-5096
United States
:
jamaal edwards,
contract specialist
Phone: 2157374179